RU2016138574A3 - - Google Patents

Download PDF

Info

Publication number
RU2016138574A3
RU2016138574A3 RU2016138574A RU2016138574A RU2016138574A3 RU 2016138574 A3 RU2016138574 A3 RU 2016138574A3 RU 2016138574 A RU2016138574 A RU 2016138574A RU 2016138574 A RU2016138574 A RU 2016138574A RU 2016138574 A3 RU2016138574 A3 RU 2016138574A3
Authority
RU
Russia
Application number
RU2016138574A
Other languages
Russian (ru)
Other versions
RU2016138574A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016138574A publication Critical patent/RU2016138574A/ru
Publication of RU2016138574A3 publication Critical patent/RU2016138574A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016138574A 2014-03-05 2015-03-04 Способ лечения депрессии и депрессивного эпизода тяжелой степени RU2016138574A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461948529P 2014-03-05 2014-03-05
US61/948,529 2014-03-05
US201462061417P 2014-10-08 2014-10-08
US62/061,417 2014-10-08
PCT/US2015/018701 WO2015134585A1 (en) 2014-03-05 2015-03-04 Method for treating depression and major depressive disorder

Publications (2)

Publication Number Publication Date
RU2016138574A RU2016138574A (ru) 2018-04-06
RU2016138574A3 true RU2016138574A3 (enExample) 2018-10-12

Family

ID=54055831

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016138574A RU2016138574A (ru) 2014-03-05 2015-03-04 Способ лечения депрессии и депрессивного эпизода тяжелой степени

Country Status (12)

Country Link
US (1) US20170137880A1 (enExample)
EP (1) EP3114239A4 (enExample)
JP (1) JP2017512204A (enExample)
KR (1) KR20160127126A (enExample)
CN (1) CN106536751A (enExample)
AU (1) AU2015227296A1 (enExample)
CA (1) CA2940683A1 (enExample)
IL (1) IL247379A0 (enExample)
MA (1) MA39485A (enExample)
MX (1) MX2016011384A (enExample)
RU (1) RU2016138574A (enExample)
WO (1) WO2015134585A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
ES2890326T3 (es) * 2017-03-30 2022-01-18 Rundle Res Llc Inhibidores de vortioxetina y MAO para tratar la depresión
US20190216803A1 (en) 2017-03-30 2019-07-18 Rundle Research, LLC Methods of treating depression with vortioxetine
EP3909600A1 (en) * 2020-05-12 2021-11-17 International Centre For Genetic Engineering And Biotechnology - ICGEB Emid2 protein as anti-cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
EP2581455A3 (en) * 2008-01-17 2013-07-10 Suregene LLC Genetic markers of mental illness
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
US20130274133A1 (en) * 2010-10-01 2013-10-17 Rigshospitalet Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
WO2012109565A1 (en) * 2011-02-10 2012-08-16 Neurotherics, Llc Genetic identification of response to antidepressant medications
US9243464B2 (en) * 2011-02-10 2016-01-26 Baker Hughes Incorporated Flow control device and methods for using same
CN104053785A (zh) * 2011-11-14 2014-09-17 综合医院公司 为患有抑郁症的受试者选择治疗方案的测定法和方法

Also Published As

Publication number Publication date
MX2016011384A (es) 2017-05-01
WO2015134585A1 (en) 2015-09-11
MA39485A (fr) 2015-09-11
RU2016138574A (ru) 2018-04-06
US20170137880A1 (en) 2017-05-18
JP2017512204A (ja) 2017-05-18
EP3114239A1 (en) 2017-01-11
IL247379A0 (en) 2016-11-30
KR20160127126A (ko) 2016-11-02
CN106536751A (zh) 2017-03-22
AU2015227296A1 (en) 2016-09-08
CA2940683A1 (en) 2015-09-11
EP3114239A4 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
BR112016017664A2 (enExample)
BR112016015519A2 (enExample)
BR112016015890A2 (enExample)
BR112016016490A2 (enExample)
BR112016016546A2 (enExample)
BR112016015865A2 (enExample)
BR112016017103A2 (enExample)
BR112016015215A2 (enExample)
BR112016016612A2 (enExample)
BR112016017031A2 (enExample)
BR112016016421A2 (enExample)
BR112016016106A2 (enExample)
BR112016012568A2 (enExample)
BR112016017516A2 (enExample)
BR112016016558A2 (enExample)
BR112016015798A2 (enExample)
BR112016015915A2 (enExample)
BR112016015779A2 (enExample)
BR112016017216A2 (enExample)
BR112016016468A2 (enExample)
BR112016017356A2 (enExample)
BR112016016863A2 (enExample)
BR112016016459A2 (enExample)
BR112016003522A2 (enExample)
BR112016014482A2 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190129